Cosmetic Corner: Botox Biosimilar Update, New Launches From Cynosure Lutronic and HydraFacial
AEON Biopharma Receives Positive Outcome From FDA in Botox Biosimilar Meeting AEON Biopharma, Inc. and U.S. Food and Drug Administration (FDA) are aligned on the regulatory pathway for ABP-450 (prabotulinumtoxinA) injection as a biosimilar utilizing BOTOX (onabotulinumtoxinA) as the reference product. The Company is actively planning comparative analytical studies, which are expected to commence in […]